Umbilical cord blood transplantation has been increasingly used over the past years for both malignant and non-malignant hematologic and other diseases as an alternative to mismatched-related or matched-unrelated bone marrow or peripheral blood hematopoietic stem cell transplantation. A disadvantage of cord blood is its low cell content which limits cord blood transplantation to generally low w...

Large body of clinical and scientific data has been generated since the first cord blood transplantation (CBT) was performed in 1989. Superior immune plasticity of CB grafts, that allows for less stringent HLA matching, is especially valuable in the face of a persistently growing need for unrelated donor (UD) transplants. Limited cell dose remains the main setback of CBT, particularly in adult ...

Background: The main objective of this study was to systematically review the reported potency of cord blood stem cells in treating patients with neurological disorders such as cerebral palsy.  Methods: PubMed, Scopus, and Cochrane were searched thoroughly on September 2016 using the following search terms: “Umbilical cord blood stem cells” AND “development” AND “cerebral palsy” to find articl...

Stem cell transplantation is the only curative treatment for a number of haematological and oncological diseases including lymphomas, leukaemias and several solid tumours. Recently the indications for this kind of treatment have been extended into other fields of internal medicine, e.g. autoimmune diseases. For stem cell transplantation it is necessary to have a graft consisting either of autol...

stem cells are undifferentiated self regenerating multi potential cells. there are three types of stem cells categories by the ability to form after cells and correlated with the body’s development process. totipotent: these stem cells can form an entire organism such as fertilized egg. ploripotent: ploripotent cells are those that can form any cell in the body but cannot form an entire organis...

background the aim of this study was the ex vivo expansion of umbilical cord blood hematopoietic stem cells on biocompatible nanofiber scaffolds. materials and methods cd133+ hematopoietic stem cells were separated from umbilical cord blood using midimacs (positive selection) system by means of monocolonal antibody cd133 (microbeads) subsequently, flowcytometry method was done to assess the pur...

Transplant 2004; 33: 1061–1063 15. Ballen KK. New trends in umbilical cord blood transplantation. Blood 2005; 105: 3786–3792 16. Wils EJ, Cornelissen JJ. Thymopoiesis following allogeneic stem cell transplantation: new possibilities for improvement. Blood Rev 2005; 19: 89–98 17. Mezey E, Chandross KJ, Harta G, Maki RA, Mc Kercher SR. Turning blood into brain: cells bearing neuronal antigens gen...

Cord blood-derived neural stem cells (NSCs) are proposed as an alternative cell source to repair brain damage upon transplantation. However, there is a lack of data showing how these cells are driven to generate desired phenotypes by recipient nervous tissue. Previous research indicates that local environment provides signals driving the fate of stem cells. To investigate the impact of these lo...

Over 20.000 umblical cord blood transplantations (UCBT) have been carried out around the world. Indeed, UCBT represents an attractive source of donor hematopoietic stem cells (HSCs) and, offer interesting features (e.g., lower graft-versus-host disease) compared to bone marrow transplantation (BMT). Thereby, UCBT often represents the unique curative option against several blood diseases. Recent...